Author of

• 25948

  +

  P2.11 - Screening and Early Detection (Not CME Accredited Session) (ID 960)

  • Event: WCLC 2018
  • Type: Poster Viewing in the Exhibit Hall
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall

  • 27131

    +

    P2.11-09 - Uncommon EGFR Mutation Analysis from Urine of Lung Cancer Patients (ID 13950)

    16:45 - 18:00  |  Author(s): Fadillah Putri Patria
    • Abstract
    • Slides

    Background
    

    Lung cancer is a type of cancer with a very high mortality rate, mostly caused by misdiagnosis of the cancer during early stage when most of the treatment are supposed to be adequate. A type of medical diagnosis known as molecular diagnosis has been developed to alleviate this problem. One example of this diagnosis method is targeted therapy on specific DNA for biomarking. In Non-Small Cell Lung Cancer (NSCLC), mutation in EGFR gene will activate Tyrosine Kinase response and the decay of auto inhibitor system. The standard method to identify EGFR mutations is tissue biopsy that requires the sampling of tissue. A secondary method using molecular diagnosis has been developed to increase the succes rate of the lung cancer diagnosis. Plasma circulating tumor DNA (ctDNA) is a DNA fragment which contains tumor-specific alteration, mostly found in body fluids such as blood, urine, saliva, sputum, and pleura. ctDNA fragments in urine can easily be sampled for biopsy, a type of molecular analysis on the urine to look for these altered DNAs can be used as another option for lung cancer detection as well.

    a9ded1e5ce5d75814730bb4caaf49419 Method
    

    A total of 30 frozen urine sample were collected from NSCLC patients. The patients were diagnosed with positive EGFR mutation from the cell line. The exon 18 and 20 of EGFR were the target for mutational analysis, ctDNA from urine was amplified using polymerase with original primer for sequencing.

    4c3880bb027f159e801041b1021e88e8 Result
    

    Among 30 samples, 6% was detected as G719X mutations, 50% detected as T790M mutations, 60% was detected as Q787Q mutations. Urine samples was determined as viable testing methods like DNA direct sequencing from tissue.

    8eea62084ca7e541d918e823422bd82e Conclusion
    

    Lung cancer harboring exon 18 and exon 20 mutations can be detected using DNA direct sequencing method. The use of urine biopsy was proven to be viable as an alternative to tissue biopsy when tissue isn’t available for molecular testing.

    6f8b794f3246b0c1e1780bb4d4d5dc53

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.